+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hormone Refractory Prostate Cancer Drug"

Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 450 Pages
  • Global
From
Metastatic Hormone Refractory Prostate Cancer - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Metastatic Hormone Refractory Prostate Cancer - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • June 2024
  • 200 Pages
  • Global
From
Hormone Refractory Prostate Cancer Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Hormone Refractory Prostate Cancer Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2024
  • 73 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

The Hormone Refractory Prostate Cancer Drug market is a subset of the larger Prostate Cancer Drugs market. It is composed of drugs that are used to treat prostate cancer that has become resistant to hormone therapy. These drugs are used to reduce the size of the tumor, slow the growth of the cancer, and reduce symptoms. Commonly used drugs in this market include abiraterone, enzalutamide, cabazitaxel, and docetaxel. Companies in the Hormone Refractory Prostate Cancer Drug market include AstraZeneca, Janssen Pharmaceuticals, Sanofi, Pfizer, and Bayer. Show Less Read more